The New England Journal of MedicineA Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

SEP-363856, a non-D2-receptor binding antipsychotic, reduced the PANSS total score from baseline more than the placebo in this 4-week experiment comprising individuals with acute exacerbations of schizophrenia. Longer and larger trials are required to confirm SEP-363856’s effects and side effects as well as its efficacy in comparison to other medications currently used to treat schizophrenia patients.